KBI-BIOPHARMA
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdspartneren Cloud2321.11.2025 18:45:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Cloud23, en næstegenerations konsulentvirksomhed, der integrerer data og kunstig intelligens med henblik på at drive digital transformation. Cloud23 er baseret i Sydafrika og leverer intelligente, platformsbaserede løsninger til kunder inden for sektorer som finans, telekommunikation, sundhedsvæsen og produktion. Virksomhedens ydelser spænder over Salesforce-rådgivning og -implementering, managed services og ai-strategi, hvilket giver organisationer mulighed for at modernisere kundeengagement, optimere driften og skabe målbare resultater. “Vores mål hos Cloud23 har altid været at forenkle transformation gennem smart, skalerbart design,” udtaler Ram Ramakrishnan, stifter og administrerende direktør for Cloud23. “Vi fokuserer på at afstemme teknologi med formål og levere resultater, der understøtter langsigtet vækst, kundeværdi og innovation. Samarbejdet med Andersen Consulting giver os mulighed for at styrke vores mission og opnå en stø
AI Takes Out the Trash: Largest U.S. Recycling Project to Extend Landfill Life for Virginia Residents21.11.2025 13:30:00 CET | Press release
Southeastern Public Service Authority of Virginia contracts with AMP to cost-effectively process municipal solid waste, boost recycling and landfill diversion rates The Southeastern Public Service Authority of Virginia (“SPSA”), the regional waste authority for South Hampton Roads, has signed a 20-year contract with Commonwealth Sortation LLC, an affiliate of AMP Robotics Corporation (together, “AMP”), to provide solid waste processing services for SPSA’s eight member communities and their 1.2 million residents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120330758/en/ Building on a nearly two-year pilot project in Portsmouth—which featured an AMP ONE™ system capable of processing up to 150 tons of locally sourced municipal solid waste (“MSW”) per day—AMP will now scale its technology region-wide. Under this long-term partnership, which will facilitate the largest recycling project in the country, AMP will deploy addit
RSA Recognized for the Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Access Management21.11.2025 13:00:00 CET | Press release
RSA, the security-first identity leader, today announced that RSA® ID Plus has been recognized for the second year in a row in the Gartner® Magic Quadrant™ for Access Management. “The RSA Access Management strategy has never been about being everything to everyone,” said Greg Nelson, RSA CEO. “We specialize in protecting organizations where risk tolerance is at its lowest and security requirements are at their highest. Our focus is intentional: providing security-first access management that supports compliance, ensures resilience, and delivers confidence at scale.” “RSA specializes in the workforce access management use cases where security, compliance, and operational resilience are non-negotiables,” said Jim Taylor, RSA President, Chief Product and Strategy Officer. “Our product development strategy will continue to emphasize the key qualities that highly regulated industries prioritize, including user experience, strong support for workforce management, and intelligent posture mana
NIQ and Amazon Marketing Cloud (AMC) Collaborate to Measure Reach and Impact of Cross-Platform Ad Campaigns in Italy21.11.2025 09:00:00 CET | Press release
NIQ and Amazon Marketing Cloud (AMC) have announced a new collaboration to study the effectiveness of cross-platform advertising across linear TV and Amazon Ads inventory in Italy. Through the collaboration advertisers and agencies will gain actionable insights into the relative performance of ad placements across digital, linear TV and streaming environments, including how each contributes to incremental reach and influences product purchases on Amazon’s ecommerce platforms. The insights are made possible by using high-quality data from Sinottica®—a well-established single-source consumer panel in Italy owned by NIQ—with data from Amazon Marketing Cloud. Specifically, the research will leverage Sinottica’s linear TV data alongside several Amazon inventory sources, including Amazon DSP, Sponsored Ads (Products, Brands, Display), and Streaming TV (Prime Video, Twitch, Fire TV). This approach will enable a deeper understanding of how ad exposure across digital and TV channels translates
Ahead of Holiday Season, Visa Identifies Five Transformative Forces Reshaping Global Payment Security20.11.2025 19:50:00 CET | Press release
New Biannual Threats Report Reveals Fundamental Shift in Fraud Operations as Criminals Adopt Industrial-Scale Tactics To celebrate International Fraud Awareness Week, Visa (NYSE: V) today released its Fall 2025 Biannual Threats Report, revealing five forces that are transforming the global payments security landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120412198/en/ The report, produced by Visa's Payment Ecosystem Risk and Control (PERC) team, draws on intelligence from Visa's global network to identify how criminal operations are evolving with unprecedented speed, scale, and sophistication. "The payments ecosystem is experiencing a paradigm shift in how fraud operates," said Paul Fabara, Chief Risk and Client Services Officer at Visa. "Criminals are no longer working as opportunistic individuals-- they're operating like tech startups, building reusable infrastructure and deploying systematic, industrial-scale
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom